Stocks · Healthcare · Biotechnology
Cartesian Therapeutics, Inc. RNAC
$7.36 +1.94% Close, Oct 2, 2026 · NASDAQ · Market cap $216.2M
Expensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -6679.7% from -8577.6% a year earlier.
- The diluted share count rose 12.9% in a year.
- Revenue over the last four quarters was $1.5M, up 44.0% from a year earlier, accelerating from -94.8% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 18%
- Revenue growth, 3-year CAGRBottom 2%
- Revenue growth accelerationTop 3%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 41%
- Gross marginBottom 2%
- Operating marginBottom 5%
- Accruals (lower is better)Top 9%
- Interest coverBottom 12%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 9%
- Free-cash-flow yieldBottom 13%
- EBITDA / enterprise valueBottom 4%
- Sales / enterprise valueBottom 9%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 29%
- 6-month returnTop 41%
- 1-year return vs S&P 500Bottom 24%
- Distance from 52-week highBottom 49%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 24%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 45%
- Upside to consensus price targetTop 15%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 36%
- Maximum drawdown, 3 yearsBottom 24%
- Beta vs S&P 500 (lower is better)Bottom 3%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -94.8% | 44.0% | ↑ |
| Gross margin | 100.0% | -766.4% | ↓ |
| Operating margin | -8577.6% | -6679.7% | ↑ |
| FCF margin | -4338.6% | -5291.5% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 44.0% | -94.8% | ↑ | Top 18% |
| Gross margin | -766.4% | 100.0% | ↓ | Bottom 2% |
| Operating margin | -6679.7% | -8577.6% | ↑ | Bottom 5% |
| Net margin | -10422.5% | -3534.1% | ↓ | — |
| Free-cash-flow margin | -5291.5% | -4338.6% | ↓ | — |
| Return on invested capital | -30.8% | — | Bottom 41% | |
| Revenue growth, 3-year CAGR | -70.7% | — | Bottom 2% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -24.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 625.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -88.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -115.8×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.03%
- Shareholder yield
- -0.03%
- Share count change, 1 year
- +12.9%
- Share count change, 3-year CAGR
- +80.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -15.0%
- Average 2-day reaction, last 8
- +3.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $25.00
- Target vs current price
- +239.7%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 80%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +152.4% | +4.9% | +4.0% | +8.7% | — |
| Apr 30, 2026 | -73.8% | -3.9% | +28.9% | +11.4% | +20.4% |
| Mar 9, 2026 | -68.3% | +31.7% | +7.9% | -8.9% | -6.4% |
| Nov 6, 2025 | -70.4% | -1.6% | -1.2% | -10.0% | -9.6% |
| Aug 7, 2025 | +165.8% | -6.6% | +3.8% | -11.3% | -28.1% |
| May 8, 2025 | -11.5% | +2.7% | -1.7% | -8.0% | +23.0% |
| Mar 20, 2025 | +24.4% | +3.0% | -3.8% | -31.6% | -32.6% |
| Nov 7, 2024 | -44.9% | -0.4% | -17.9% | +10.3% | -7.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $0.46 | -$0.88 | +152.4% | — |
| Apr 30, 2026 | -$1.46 | -$0.84 | -73.8% | $78,000 |
| Mar 9, 2026 | -$1.38 | -$0.82 | -68.3% | $947,000 |
| Nov 6, 2025 | -$1.38 | -$0.81 | -70.4% | $452,000 |
| Aug 7, 2025 | $0.50 | -$0.76 | +165.8% | $298,000 |
| May 8, 2025 | -$0.68 | -$0.61 | -11.5% | $1.1M |
| Mar 20, 2025 | -$0.59 | -$0.78 | +24.4% | $759,000 |
| Nov 7, 2024 | -$1.13 | -$0.78 | -44.9% | $387,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 89.71× | — | — | Bottom 9% |
| Free-cash-flow yield | -36.14% | — | — | Bottom 13% |
| Earnings yield | -79.35% | — | — | Bottom 9% |
P/E over the past five years
Range 4.3× – 6.0× since Mar 31, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.6%
- 200-day average slope (20 days)
- +0.6%
- Distance from 50-day average
- -13.7%
- Distance from 200-day average
- -4.6%
- RSI (14)
- 32.9
- Relative volume
- 1.52×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 47.4%
- Volatility vs own 5-year history
- 1th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.76
- Correlation with S&P 500
- 0.44
- Current drawdown from 1-year high
- -30.5%
- Maximum drawdown, 3 years
- -85.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 5, 2021 | Jun 5, 2026 | -96.2% | 1338 days | Not yet recovered |
| Sep 29, 2020 | Oct 1, 2020 | -35.9% | 2 days | 14 days (Oct 21, 2020) |
| Nov 27, 2020 | Dec 16, 2020 | -14.6% | 13 days | 19 days (Jan 14, 2021) |
| Oct 28, 2020 | Oct 30, 2020 | -11.9% | 2 days | 19 days (Nov 27, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $216.2M
- EPS, diluted (TTM)
- -$5.84
- Revenue (TTM)
- $1.5M
- 52-week range
- $5.60 – $11.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $85.1M | $110.8M | $26.0M | $38.9M | $2.8M |
| Gross profit | $85.1M | $108.7M | $26.0M | $38.9M | $2.8M |
| Operating income | -$4.6M | $14.5M | -$86.4M | -$43.9M | -$86.7M |
| Net income | -$25.7M | $35.4M | -$219.7M | -$77.4M | -$130.3M |
| EPS (diluted) | -$6.60 | $3.00 | -$49.76 | -$3.29 | -$5.02 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $387,000 | -$759,000 | $1.1M | $298,000 | $452,000 | $947,000 | $78,000 | $0 |
| Net income | -$24.2M | -$10.3M | -$17.7M | $15.9M | -$35.9M | -$92.6M | -$39.2M | $13.7M |
| EPS (diluted) | -$1.13 | -$0.07 | -$0.68 | $0.60 | -$1.38 | -$3.46 | -$1.46 | $0.46 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$60.4M | -$31.6M | -$51.2M | -$23.7M | -$73.9M |
| Capital expenditure | -$1.1M | -$1.2M | -$206,000 | -$9.1M | -$5.5M |
| Free cash flow | -$61.5M | -$32.8M | -$51.4M | -$32.8M | -$79.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $52.0M | $39.0M | -$6.2M | $124.4M | -$301,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $147.6M
- Total assets
- $318.6M
- Total liabilities
- $443.9M
- Total debt
- $63.9M
- Net debt
- -$83.8M
- Shareholders’ equity
- -$125.2M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 1,803,282
- Days to cover
- 17.00
- Change vs previous report
- -0.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Apr 5, 2024
- 1-for-30